Last updated: 2026-10-13 09:19:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Medicinova, Inc. (MNOV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.55, with a market capitalisation of $74.82M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.17 to $3.90. This page covers its latest market performance, valuation, price trends and company information.
$74.82M | |
$1.55 | |
$16.12 | |
$1.12 | |
$1.54 | |
-- | |
330.62K | |
-- | |
$3.90 | |
$1.17 | |
-- | |
-- |
Medicinova, Inc. (MNOV) is trading at $1.55 in pre-market trading as of 2026-10-13 08:03:00, up 0.65% ($0.01) from the previous close of $1.54
Pre-market trading shows how investors are pricing MNOV before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Medicinova, Inc. (MNOV) moved from $1.78 to $1.55, representing a decline of 12.92% ($0.23).
The stock traded between $1.48 and $1.89 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 142.51 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 14.0%
MNOV is currently trading at $1.55, placing it 14.0% of the way from its 52-week low of $1.17 to its 52-week high of $3.90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Medicinova, Inc. (MNOV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.